Posting of notice of General Meeting

EDX Medical Group PLC

17 June 2025

 

EDX Medical Group plc: EDX

17 June 2025

17 June 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

Posting of Notice of General Meeting

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that a general meeting will be held at the Heritage Centre, Royal School of Medicine, 2nd floor, 1 Wimpole St, Westminster, London, W1G 0AE on 3 July at 11am.

The Notice of General Meeting and Form of Proxy will be posted today, 17 June 2025, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/

Contacts:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
IFC Advisory (Investor Relations)
Tim Metcalfe	[phone]
Graham Herring
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]

Notes for Editors:

About EDX Medical Group

EDX Medical Group Plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

 

END